Professional paper
Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review
Marija Gamulin
; Division for Genitourinary Tumors, Department of Oncology, University Hospital Center Zagreb, Zagreb, Croatia
Eric Nham
; University of Zagreb School of Medicine, Zagreb, Croatia
Deni Rkman
; University of Zagreb School of Medicine, Zagreb, Croatia
Zrna Antunac Golubić
; Division for Genitourinary Tumors, Department of Oncology, University Hospital Center Zagreb, Zagreb, Croatia
Robert Likić
orcid.org/0000-0003-1413-4862
; Division for Clinical Pharmacology and Therapeutics, Department of Internal Medicine, University Hospital Center Zagreb, Zagreb, Croatia
Abstract
Aim To assess diseases outcomes and tolerability of reallife second-line nivolumab in a series of metastatic renal
cell carcinoma (mRCC) patients.
Methods This retrospective chart review involved prospectively monitored patients (named patient program)
treated with second-line nivolumab for mRCC at the University Hospital Centre Zagreb from February 2016 to
March 2018.
Results The study enrolled 30 patients, 5 of whom (16.7%)
had a complete response. The mean±standard deviation
therapeutic response time to nivolumab treatment was
14.07±8.92 months, with a minimum treatment duration
of 2 months and a maximum of 24 months. The median
duration of therapy was 17 months (mean: 15.8 months;
range: 3-24 months), and 50% (n=15/30) of patients remained alive at the end of follow up. The most common
adverse events associated with nivolumab were fatigue
(26.67%; n=8/30), anemia (10.0%; n=3/30), adrenal insufficiency (6.67%; n=2/30: G1=1, G2=1), grade 2 pneumonitis (6.67%; n=2/30), grade 2 neuropathy (6.67%; n=2/30),
rash (6.67%; n=2/30: G1=1, G2=1), and hepatitis (3.33%;
n=1/30).
Conclusion The present study indicates acceptable patient responses and tolerability of nivolumab in mR
Keywords
Hrčak ID:
274611
URI
Publication date:
31.8.2020.
Visits: 607 *